Neurodon
Neurodon is dedicated to treating cellular stress at its root to develop disease-modifying therapeutics that have the potential to change patients' lives. Their focus is on regulating impaired calcium transport in cells to relieve stress pathways, aiming to revolutionize medicine by addressing the core mechanisms of diseases such as diabetes, Alzheimer’s, Parkinson’s, and rare diseases.
Industries
Nr. of Employees
small (1-50)
Patents
Products
NRDN-101 — orally available SERCA activator (diabetes candidate)
A disease-modifying, orally available small-molecule allosteric activator of SERCA developed to restore ER calcium homeostasis in pancreatic beta cells and attenuate beta cell dysfunction and death.
NRDN-201 / NDC-1173 — neurodegeneration candidate (Alzheimer’s and Parkinson’s)
Small-molecule SERCA activators developed for neuroprotective effects including improved learning and memory, reduced neuroinflammation, preservation of synaptic integrity, and prevention of dopaminergic neuron loss in preclinical models.
NRDN-301 — muscular disease candidate (Duchenne muscular dystrophy)
Small-molecule activators of SERCA targeting skeletal muscle cells to restore calcium dynamics, reduce necrosis and fibrosis, and improve muscle contraction and function in preclinical DMD models.
NRDN-101 — orally available SERCA activator (diabetes candidate)
A disease-modifying, orally available small-molecule allosteric activator of SERCA developed to restore ER calcium homeostasis in pancreatic beta cells and attenuate beta cell dysfunction and death.
NRDN-201 / NDC-1173 — neurodegeneration candidate (Alzheimer’s and Parkinson’s)
Small-molecule SERCA activators developed for neuroprotective effects including improved learning and memory, reduced neuroinflammation, preservation of synaptic integrity, and prevention of dopaminergic neuron loss in preclinical models.
NRDN-301 — muscular disease candidate (Duchenne muscular dystrophy)
Small-molecule activators of SERCA targeting skeletal muscle cells to restore calcium dynamics, reduce necrosis and fibrosis, and improve muscle contraction and function in preclinical DMD models.
Services
End-to-end preclinical development including lead optimization, in vitro and in vivo efficacy testing, basic PK/PD and tolerability studies to generate IND-enabling datasets.
Research collaborations with academic investigators and disease foundations to test therapeutic hypotheses, validate biomarkers, and leverage core facilities for specialized assays.
End-to-end preclinical development including lead optimization, in vitro and in vivo efficacy testing, basic PK/PD and tolerability studies to generate IND-enabling datasets.
Research collaborations with academic investigators and disease foundations to test therapeutic hypotheses, validate biomarkers, and leverage core facilities for specialized assays.
Expertise Areas
- SERCA-targeted small-molecule drug discovery
- Preclinical efficacy and safety studies
- Neuroprotection and neurodegeneration therapeutics
- Metabolic disease therapeutics (diabetes)
Key Technologies
- Small-molecule allosteric modulation
- SERCA (ER calcium pump) modulation
- In vivo rodent disease models
- Behavioral and cognitive assays (e.g., water maze)
News & Updates
U.S. Senator Todd Young recently toured Neurodon’s laboratory and offices at its headquarters in Crown Point, Indiana, to learn about the company’s progress towards clinical translation of its therapeutics for Alzheimer’s, diabetes, and rare diseases.
Neurodon has entered into an agreement with Dr. Shingo Kajimura at Harvard Medical School to assess the potential of Neurodon’s molecules in metabolic diseases such as diabetes and obesity.
Neurodon has begun essential studies to enable the submission of an Investigational New Drug (IND) application for NDC-0009, a molecule to treat Type 1 Diabetes.
Neurodon received a nearly $3 million grant from the NIH to support the development of its small molecule therapeutics for Alzheimer’s, demonstrating neuroprotective properties and potential to improve memory and cognition.
Neurodon’s drug NDC-0009 has the potential to treat both Type 1 and Type 2 diabetes and may be a gamechanger for patients by restoring beta cell health.
Neurodon scientists have validated a new approach to prevent neuronal death by increasing SUMOylation, a natural protective process, which could be a breakthrough in neurodegenerative disease treatment.
U.S. Senator Todd Young recently toured Neurodon’s laboratory and offices at its headquarters in Crown Point, Indiana, to learn about the company’s progress towards clinical translation of its therapeutics for Alzheimer’s, diabetes, and rare diseases.
Neurodon has entered into an agreement with Dr. Shingo Kajimura at Harvard Medical School to assess the potential of Neurodon’s molecules in metabolic diseases such as diabetes and obesity.
Neurodon has begun essential studies to enable the submission of an Investigational New Drug (IND) application for NDC-0009, a molecule to treat Type 1 Diabetes.
Neurodon received a nearly $3 million grant from the NIH to support the development of its small molecule therapeutics for Alzheimer’s, demonstrating neuroprotective properties and potential to improve memory and cognition.
Neurodon’s drug NDC-0009 has the potential to treat both Type 1 and Type 2 diabetes and may be a gamechanger for patients by restoring beta cell health.
Neurodon scientists have validated a new approach to prevent neuronal death by increasing SUMOylation, a natural protective process, which could be a breakthrough in neurodegenerative disease treatment.